Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
DNTH
SellHot AirDianthus Therapeutics, Inc. · Healthcare · United States · $5.9B · Avg Vol: $72M/d
COMPANY DESCRIPTION
Dianthus Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing next-generation complement inhibitors designed to treat severe and rare autoimmune diseases. The company's competitive moat is rooted in its novel scientific approach to complement system biology and proprietary antibody drug candidates engineered for enhanced potency and prolonged half-life. Dianthus aims to address significant unmet medical needs within underserved autoimmune conditions, representing a high-potential player in targeted immunology.
FINANCIAL SUMMARY (USD)
| Year | 2021 | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1.5M | 6.4M | 2.8M | 6.2M | 2.0M | 8.4% | 1.9M | 1.8M | 1.7M | -7.7% |
| EPS | -0.88 | -0.52 | -2.29 | -2.55 | -4.20 | — | -4.24 | -3.83 | -4.62 | — |
| Shares | 14.8M | 54.7M | 54.7M | 31.1M | 43.2M | +191.7% | 55.9M | — | — | — |
| Debt | 0 | 0.8M | 0.6M | 1.5M | 1.4M | 20.7% | 1.3M | — | — | — |
| Equity | -17.2M | 73.7M | 168.9M | 352.5M | 493.4M | 88.5% | — | — | — | — |
| Op CF | -9.9M | -29.1M | -36.9M | -78.2M | -129.1M | — | -155.4M | — | — | — |
| Inv CF | -33.0K | -59.8M | 20.3M | -286.8M | -122.8M | — | — | — | — | — |
| Fin CF | 14.9M | 96.7M | 133.6M | 255.6M | 280.1M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of DNTH are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| DNTH | Dianthus Therapeutics, Inc.(you) | $5.9B | 23 | Sell |
| DFTX | Definium Therapeutics, Inc. | $5.5B | 22 | Sell |
| ORKA | Oruka Therapeutics, Inc. | $6.0B | 27 | Sell |
| SYRE | Spyre Therapeutics, Inc. | $8.0B | 23 | Sell |
| MIRM | Mirum Pharmaceuticals, Inc. | $5.9B | 30 | Sell |
| SRRK | Scholar Rock Holding Corporation | $7.0B | 19 | Strong Sell |
| CGON | CG Oncology, Inc. | $6.6B | 17 | Strong Sell |
| MANE | Veradermics, Incorporated | $4.1B | 22 | Sell |
| IBRX | ImmunityBio, Inc. | $8.5B | 22 | Sell |
| IMVT | Immunovant, Inc. | $8.5B | 21 | Sell |
Peer medians: ROE -30.8% · P/E 27.0x · Gross margin 58.1%